ADHD isn’t just a lack of focus or attention, it’s a serious neurodevelopmental condition that can impact long-term health and even life expectancy.
Research shows that people with untreated ADHD may live up to 13 years less than those without ADHD. (Barkley et al., Journal of Attention Disorders, 2019)
This is linked to preventable risks — higher rates of accidents, impulsive behaviours, substance misuse, and untreated comorbidities such as anxiety and depression.
There is encouraging evidence too:
Studies have shown that individuals who began ADHD medication within three months of diagnosis had a significantly lower all-cause mortality rate, mainly due to fewer deaths from accidents. Early and consistent treatment also reduces risky behaviours and improves long-term outcomes in education, work, and wellbeing. (Li et al., JAMA, 2024)
Early detection and intervention can save lives as well as increase quality of life.
That’s why at Braingaze, we’re committed to helping patients access diagnosis and treatment sooner. Our products BGaze Clinic and BGaze Focus are based on patented eye-vergence biomarkers which can be used to detect and trained to improve symptoms of ADHD.
By improving accuracy and reducing delays in diagnosis, we aim to make early ADHD intervention the standard — protecting health and improving long-term outcomes.